Karen Chilcott Holdridge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karen Chilcott Holdridge has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Albert J Allen
Lilly Research Laboratories, Indianapolis, IN, USA
1 shared publication- Angelina Lee
Westat, Rockville, MD, United States
1 shared publication David Dunn
Indiana University School of Medicine, Indianapolis, IN, USA
1 shared publicationJoachim F Wernicke
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
1 shared publication- Joanna Kubisiak
Westat, Rockville, MD, United States
1 shared publication John P. Houston
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100547
Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer’s disease
- 1 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100547
Open AccessIncrease in healthcare utilization and Medicare payment with progression of preclinical Alzheimer’s disease
- 1 July 2010
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 5 (3) , 203-211
Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database.
Abstract: Mortality rates across matched cohorts of hospitalized patients treated with IM olanzapine, haloperidol, and/or ziprasidone in a hospital database were compared. Using propensity score matching, matched cohorts of IM olanzapine- (N=2,984) and IM haloperidol-treated patients (N=2,984) and IM olanzapine- (N=2,876) and IM ziprasidone-treated patients (N=2,876) were obtained. The study outcome was in-hospital death within 2 days of administering IM antipsychotic. Incidence of death was not statistically different between olanzapine-ziprasidone cohorts (OR=1.21, 95% CI 0.92-1.59). The olanzapine cohort demonstrated a significantly lower death incidence than the haloperidol cohort (OR=0.73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone.
- 1 July 2010
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 5 (3) , 203-211
Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database.
Abstract: Mortality rates across matched cohorts of hospitalized patients treated with IM olanzapine, haloperidol, and/or ziprasidone in a hospital database were compared. Using propensity score matching, matched cohorts of IM olanzapine- (N=2,984) and IM haloperidol-treated patients (N=2,984) and IM olanzapine- (N=2,876) and IM ziprasidone-treated patients (N=2,876) were obtained. The study outcome was in-hospital death within 2 days of administering IM antipsychotic. Incidence of death was not statistically different between olanzapine-ziprasidone cohorts (OR=1.21, 95% CI 0.92-1.59). The olanzapine cohort demonstrated a significantly lower death incidence than the haloperidol cohort (OR=0.73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone.
- Open Access
- 21 June 2007
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 49 (7) , 498-502
Seizure risk in patients with attention‐deficit‐hyperactivity disorder treated with atomoxetine
The comorbidity of seizures, epilepsy, and attention‐deficit‐hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure‐related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database and the atomoxetine postmarketing spontaneous adverse event database. Review of clinical trial data indicated that the crude incidence rates of seizure adverse events were between 0.1 and 0.2%, and were not significantly different between atomoxetine, placebo, and methylphenidate. Only 2% of the postmarketing spontaneous reports of seizure events were classified as having no clear contributing or confounding factors, and the reporting rate (8 per 100 000 patients exposed) was within the expected range of population‐based incidence. Although children with ADHD are increasingly recognized as being at an elevated risk for seizures, treatment of ADHD symptoms with atomoxetine does not appear to elevate this risk further. The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD.
- 21 June 2007
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 49 (7) , 498-502
Open AccessSeizure risk in patients with attention‐deficit‐hyperactivity disorder treated with atomoxetine
The comorbidity of seizures, epilepsy, and attention‐deficit‐hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure‐related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database and the atomoxetine postmarketing spontaneous adverse event database. Review of clinical trial data indicated that the crude incidence rates of seizure adverse events were between 0.1 and 0.2%, and were not significantly different between atomoxetine, placebo, and methylphenidate. Only 2% of the postmarketing spontaneous reports of seizure events were classified as having no clear contributing or confounding factors, and the reporting rate (8 per 100 000 patients exposed) was within the expected range of population‐based incidence. Although children with ADHD are increasingly recognized as being at an elevated risk for seizures, treatment of ADHD symptoms with atomoxetine does not appear to elevate this risk further. The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD.